Arcus Biosciences, Inc. (RCUS)
Health Care / Biotechnology
S&P SmallCap 600$21.87
Below average on several measures. Research carefully.
Weak
Score based on 4 of 5 models — moderate confidence
Is Arcus Biosciences, Inc. a Good Investment in 2026?
Arcus Biosciences, Inc. (RCUS) scores 4.9 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Graham model is the most favorable, rating Arcus Biosciences, Inc. as Neutral. However, the Greenblatt Magic Formula model rates it Caution — Bottom half (rank 94%). Arcus Biosciences, Inc. ranks #605 out of 1127 stocks in the Health Care sector.
This summary is algorithmically generated and is not financial advice.
Key Metrics
Valuation
Currently unprofitable — fair value estimate not available.
Fair value estimate not available for this stock.
5-Model Analysis
Each model evaluates this stock from a different angle. Combined, they form the composite score above.
Piotroski
Caution
1/9
Buffett
Caution
Business quality & competitive moat
Graham
Neutral
Price vs intrinsic value
Lynch
Limited Data
Growth rate vs price (PEG)
Greenblatt
Caution
Bottom half (rank 94%)
Frequently Asked Questions
Is Arcus Biosciences, Inc. (RCUS) a good investment?
What is Arcus Biosciences, Inc.'s Piotroski F-Score?
Is RCUS overvalued or undervalued?
How does RCUS compare to other Health Care stocks?
What do investment models say about RCUS?
Similar Stocks
Compare RCUS with
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer